ATRX and pancreatic insulinoma: in 2023, ATRX/DAXX protein loss and ALT are extremely rare in indolent insulinomas [10]: ATRX/DAXX protein loss or mutation was observed in 3/212 (1%) tested indolent cases, compared to 5/10 (50%) tested aggressive cases.